Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $8.1 million.

  • vTv Therapeutics' Shares Outstanding (Weighted Average) rose 4651.22% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 4651.22%. This contributed to the annual value of $5.8 million for FY2024, which is 17679.26% up from last year.
  • Latest data reveals that vTv Therapeutics reported Shares Outstanding (Weighted Average) of $8.1 million as of Q3 2025, which was up 4651.22% from $6.6 million recorded in Q2 2025.
  • vTv Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $80.5 million during Q3 2022, with a 5-year trough of $1.6 million in Q4 2021.
  • For the 5-year period, vTv Therapeutics' Shares Outstanding (Weighted Average) averaged around $23.6 million, with its median value being $6.4 million (2024).
  • Per our database at Business Quant, vTv Therapeutics' Shares Outstanding (Weighted Average) crashed by 9740.97% in 2023 and then soared by 20712.36% in 2024.
  • Quarter analysis of 5 years shows vTv Therapeutics' Shares Outstanding (Weighted Average) stood at $1.6 million in 2021, then increased by 22.58% to $1.9 million in 2022, then grew by 8.6% to $2.1 million in 2023, then skyrocketed by 176.79% to $5.8 million in 2024, then skyrocketed by 39.59% to $8.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $8.1 million in Q3 2025, compared to $6.6 million in Q2 2025 and $6.6 million in Q1 2025.